Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic nonsmall-cell lung cancer in Greece: a cost-minimization analysis

Maniadakis N, Fragoulakis V, Pallis AG, Simou E, Georgoulias V

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
20019086

DOI
10.1093/annonc/mdp551

Indexing Status
Subject indexing assigned by NLM

MeSH
Adolescent; Adult; Antibodies, Monoclonal /therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy /economics /secondary; Cetuximab; Cisplatin /administration & dosage; Cost-Benefit Analysis; Deoxycytidine /administration & dosage /analogs & derivatives; Female; Greece; Humans; Lung Neoplasms /drug therapy /economics /pathology; Male; Middle Aged; Survival Rate; Taxoids /administration & dosage; Treatment Outcome; Vinblastine /administration & dosage /analogs & derivatives; Young Adult

AccessionNumber
22010001314

Date bibliographic record published
09/02/2011